LIN28A/B在肿瘤发生发展中的作用研究进展

doi:10.16288/j.yczz.24-056

[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2024, Vol. 46 ›› Issue (6): 452-465.doi: 10.16288/j.yczz.24-056

• Review • Previous Articles Next Articles

Progress on the role of LIN28A/B in tumor development and progression

Zhang Yiwen(), Huang Qin(), Wu Yanyun, Sun Yue(), Wei Yonglong()

Center for Life Sciences, Yunnan Key Laboratory of Cell Metabolism and Diseases School of Life Sciences, Yunnan University, Kunming 650504, China

Received:2024-03-07 Revised:2024-05-07 Online:2024-06-20 Published:2024-05-23
Supported by:
Open project of Yunnan Key Laboratory of Cancer Immunology Prevention and Treatment Research(KLTIPT-2023-03);Graduate Scientific Research Innovation Project of Yunnan University(KC22223021)

Abstract

Abstract:

LIN28A and its homolog LIN28B are highly conserved RNA-binding proteins that play important roles in early embryonic development, somatic cell reprogramming, metabolism and tumorigenesis. LIN28A/B are highly expressed in a variety of malignant tumors such as breast cancer. They play important roles in the initiation, maintenance, and metastasis of tumors and are associated with poor prognosis. Previous studies have shown that the main regulatory mechanisms of LIN28A/B include let-7s dependent ways and let-7s independent ways, such as directly targeting mRNA. In this review, we summarize the function and molecular regulatory mechanisms of LIN28A/B in malignant tumors such as liver cancer, breast cancer and colorectal cancer, in order to provide references for further exploring the function and mechanism of LIN28A/B and their possible roles in clinical applications.

Key words: LIN28A, LIN28B, let-7 miRNA, tumor development and progression, therapeutic targets

Zhang Yiwen, Huang Qin, Wu Yanyun, Sun Yue, Wei Yonglong. Progress on the role of LIN28A/B in tumor development and progression[J]. Hereditas(Beijing), 2024, 46(6): 452-465.

Figures/Tables 4

Fig. 1

Fig. 2

Table 1

Expression and clinical relevance of LIN28A/B in human tumor samples"

肿瘤类型	样本量	检测方法	临床相关性	参考文献
乳腺癌	569	TMA	1) LIN28A高、中、低表达的患者分别占1/3，高表达患者生存率显著低于中、低表达患者 2) LIN28A表达与HER2+乳腺癌相关	[52]
乳腺癌	33	IHC	1) 9/33 LIN28A上调，10/33 LIN28B上调 2) LIN28A与HER2亚型相关，LIN28B与三阴性乳腺癌相关	[15]
乳腺癌	190	IHC	83/190 LIN28B阳性，107/190 LIN28B阳性	[55]
乳腺癌	140	TMA	1) Lin28B在三阴性乳腺癌中的表达显著高于 Luminal和HER2亚型 2) Lin28B与临床肿瘤分级、远端转移、不良预后相关	[17]
结肠癌	45	IHC	19/45 LIN28A上调，14/45 LIN28B上调	[15]
结肠癌	228	TMA，IHC	LIN28B高表达与低生存率和高复发率相关	[16]
结直肠癌	595	IHC	1) 10% LIN28A阳性、8% LIN28B阳性、20% LIN28A/B阳性 2) LIN28A高表达与低生存率相关	[57]
胰腺导管腺癌	80	TMA，IHC	1) 23/80 LIN28B高表达 2) LIN28B表达与肿瘤晚期分级和不良预后相关	[58]
肝细胞癌	129	RT-qPCR	1) LIN28A在肿瘤中的表达频率显著高于正常组织 2) LIN28A高表达与不良预后相关	[59]
肝细胞癌	22	RT-qPCR	10/22 LIN28B阳性，但仅1/22 LIN28A阳性	[37]
肝细胞癌	162	RT-qPCR	60/162 LIN28B阳性	[37]
肝内胆管癌	20	IHC	3/20 LIN28B阳性，未检测到LIN28A阳性组织	[60]
胃癌	239	IHC， RT-qPCR	1) LIN28A在胃癌肿瘤和相应正常组织中均有表达，无显著差异 2) LIN28A表达与不良预后相关	[61]
胃腺癌	97	IHC	1) 42/97 LIN28B高表达，LIN28B在胃腺癌肿瘤中的表达高于相应正常组织 2) LIN28B与胃腺癌转移、TNM分期、肿瘤侵袭和分化相关	[62]
食道癌	161	IHC	1) LIN28A/B在食管癌中均存在表达上调 2) LIN28A/B高表达与淋巴结转移和不良预后相关	[63]
睾丸生殖细胞瘤	184	IHC	1) 90%以上肿瘤组织LIN28A阳性 2) LIN28A是睾丸生殖细胞瘤诊断的敏感标志物	[64]
卵巢生殖细胞瘤	121	IHC	1) 103/121 LIN28A阳性 2) LIN28A是卵巢生殖细胞瘤诊断的敏感标志物	[65]
卵巢上皮性肿瘤	211	RT-qPCR	1) 185/211 LIN28A阳性，127/211 LIN28B阳性 2) LIN28B高表达而非LIN28A与高死亡率相关	[66]
肾母细胞瘤	105	IHC	1) 18/105 LIN28B阳性，未检测到LIN28A阳性 2) LIN28B与高复发率和高死亡率相关	[9]

Table 1

Fig. 3

References 78

[1]	Moss EG, Lee RC, Ambros V. Ambros. The cold shock domain protein LIN-28 controls developmental timing in C. elegans and is regulated by the lin-4 RNA. Cell, 1997, 88(5): 637-646. doi: 10.1016/s0092-8674(00)81906-6 pmid: 9054503
[2]	Ambros V, Horvitz HR. Heterochronic mutants of the nematode Caenorhabditis elegans. Science, 1984, 226(4673): 409-416. doi: 10.1126/science.6494891 pmid: 6494891
[3]	Yu JY, Vodyanik MA, Smuga-Otto K, Antosiewicz- Bourget J, Frane JL, Tian SL, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Thomson. Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007, 318(5858): 1917-1920. doi: 10.1126/science.1151526 pmid: 18029452
[4]	Panella M, Mosca N, Di Palo A, Potenza N, Russo A. Mutual suppression of miR-125a and Lin28b in human hepatocellular carcinoma cells. Biochem Biophys Res Commun, 2018, 500(3): 824-827.
[5]	Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, Johnston WK, Wernig M, Newman J, Calabrese JM, Dennis LM, Volkert TL, Gupta S, Love J, Hannett N, Sharp PA, Bartel DP, Jaenisch R, Young RA. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell, 2008, 134(3): 521-533. doi: 10.1016/j.cell.2008.07.020 pmid: 18692474
[6]	Guo YQ, Chen YX, Ito H, Watanabe A, Ge XJ, Kodama T, Aburatani H. Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene, 2006, 384: 51-61. pmid: 16971064
[7]	Hother C, Rasmussen PK, Joshi T, Reker D, Ralfkiær U, Workman CT, Heegaard S, Ralfkiær E, Grønbæk K. MicroRNA profiling in ocular adnexal lymphoma: a role for MYC and NFKB1 mediated dysregulation of microRNA expression in aggressive disease. Invest Ophthalmol Vis Sci, 2013, 54(8): 5169-5175.
[8]	Cheng SW, Tsai HW, Lin YJ, Cheng PN, Chang YC, Yen CJ, Huang HP, Chuang YP, Chang TT, Lee CT, Chao AN, Chou CY, Chan SH, Chow NH, Ho CL. Lin28B is an oncofetal circulating cancer stem cell-like marker associated with recurrence of hepatocellular carcinoma. PLoS One, 2013, 8(11): e80053.
[9]	Urbach A, Yermalovich A, Zhang J, Spina CS, Zhu H, Perez-Atayde AR, Shukrun R, Charlton J, Sebire N, Mifsud W, Dekel B, Pritchard-Jones K, Daley GQ. Lin28 sustains early renal progenitors and induces wilms tumor. Genes Dev, 2014, 28(9): 971-982.
[10]	Molenaar JJ, Domingo-Fernández R, Ebus ME, Lindner S, Koster J, Drabek K, Mestdagh P, van Sluis P, Valentijn LJ, van Nes J, Broekmans M, Haneveld F, Volckmann R, Bray I, Heukamp L, Sprüssel A, Thor T, Kieckbusch K, Klein-Hitpass L, Fischer M, Vandesompele J, Schramm A, van Noesel MM, Varesio L, Speleman F, Eggert A, Stallings RL, Caron HN, Versteeg R, Schulte JH. LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. Nat Genet, 2012, 44(11): 1199-1206. doi: 10.1038/ng.2436 pmid: 23042116
[11]	Nguyen LH, Robinton DA, Seligson MT, Wu LW, Li L, Rakheja D, Comerford SA, Ramezani S, Sun XK, Parikh MS, Yang EH, Powers JT, Shinoda G, Shah SP, Hammer RE, Daley GQ, Zhu H. Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell, 2014, 26(2): 248-261. doi: 10.1016/j.ccr.2014.06.018 pmid: 25117712
[12]	West JA, Viswanathan SR, Yabuuchi A, Cunniff K, Takeuchi A, Park IH, Sero JE, Zhu H, Perez-Atayde A, Frazier AL, Surani MA, Daley GQ. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature, 2009, 460(7257): 909-913.
[13]	Balzeau J, Menezes MR, Cao SY, Hagan JP. The LIN28/let-7 pathway in cancer. Front Genet, 2017, 8: 31. doi: 10.3389/fgene.2017.00031 pmid: 28400788
[14]	Jiang S, Baltimore D. RNA-binding protein Lin28 in cancer and immunity. Cancer Lett, 2016, 375(1): 108-113. doi: S0304-3835(16)30128-8 pmid: 26945970
[15]	Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, Iliopoulos D, Gregory RI. Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell, 2011, 147(5): 1066-1079. doi: 10.1016/j.cell.2011.10.039 pmid: 22118463
[16]	King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, Rustgi AK. LIN28B promotes colon cancer progression and metastasis. Cancer Res, 2011, 71(12): 4260-4268. doi: 10.1158/0008-5472.CAN-10-4637 pmid: 21512136
[17]	Qi MY, Xia Y, Wu YJ, Zhang Z, Wang XY, Lu LY, Dai C, Song YN, Xu KY, Ji WW, Zhan LX. Lin28B-high breast cancer cells promote immune suppression in the lung pre-metastatic niche via exosomes and support cancer progression. Nat Commun, 2022, 13(1): 897. doi: 10.1038/s41467-022-28438-x pmid: 35173168
[18]	Wang TZ, Wang GY, Hao DP, Liu X, Wang D, Ning N, Li XB. Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer. Mol Cancer, 2015, 14(1): 125.
[19]	Tsialikas J, Romer-Seibert J. LIN28: roles and regulation in development and beyond. Development, 2015, 142(14): 2397-2404. doi: 10.1242/dev.117580 pmid: 26199409
[20]	Zhou JB, Ng SB, Chng WJ. LIN28/LIN28B: an emerging oncogenic driver in cancer stem cells. Int J Biochem Cell Biol, 2013, 45(5): 973-978. doi: 10.1016/j.biocel.2013.02.006 pmid: 23420006
[21]	Kim SK, Lee H, Han K, Kim SC, Choi Y, Park SW, Bak G, Lee Y, Choi JK, Kim TK, Han YM, Lee D. SET7/9 methylation of the pluripotency factor LIN28A is a nucleolar localization mechanism that blocks let-7 biogenesis in human ESCs. Cell Stem Cell, 2014, 15(6): 735-749.
[22]	Peng F, Li TT, Wang KL, Xiao GQ, Wang JH, Zhao HD, Kang ZJ, Fan WJ, Zhu LL, Li M, Cui B, Zheng FM, Wang HJ, Lam EWF, Wang B, Xu J, Liu Q. H19/let-7/LIN28 reciprocal negative regulatory circuit promotes breast cancer stem cell maintenance. Cell Death Dis, 2017, 8(1): e2569.
[23]	Zhang Y, Sun Y, Ding L, Shi WJ, Ding KS, Zhu Y. Long non-coding RNA LINC00467 correlates to poor prognosis and aggressiveness of breast cancer. Front Oncol, 2021, 11: 643394.
[24]	Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer, 2010, 17(1): F19-F36.
[25]	Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA, 2008, 14(8): 1539-1549. doi: 10.1261/rna.1155108 pmid: 18566191
[26]	Heo I, Joo C, Cho J, Ha MJ, Han JJ, Kim VN. Lin28 mediates the terminal uridylation of let-7 precursor microRNA. Mol Cell, 2008, 32(2): 276-284. doi: 10.1016/j.molcel.2008.09.014 pmid: 18951094
[27]	Wu K, Ahmad T, Eri R. LIN28A: A multifunctional versatile molecule with future therapeutic potential. World J Biol Chem, 2022, 13(2): 35-46. doi: 10.4331/wjbc.v13.i2.35 pmid: 35432768
[28]	Heo I, Joo C, Kim YK, Ha MJ, Yoon MJ, Cho J, Yeom KH, Han JJ, Kim VN. TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-MicroRNA uridylation. Cell, 2009, 138(4): 696-708. doi: 10.1016/j.cell.2009.08.002 pmid: 19703396
[29]	Kawahara H, Okada Y, Imai T, Iwanami A, Mischel PS, Okano H. Musashi1 cooperates in abnormal cell lineage protein 28 (Lin28)-mediated let-7 family microRNA biogenesis in early neural differentiation. J Biol Chem, 2011, 286(18): 16121-16130. doi: 10.1074/jbc.M110.199166 pmid: 21378162
[30]	Mayr F, Heinemann U. Mechanisms of Lin28-mediated miRNA and mRNA regulation—a structural and functional perspective. Int J Mol Sci, 2013, 14(8): 16532-16553.
[31]	Gewalt T, Noh KW, Meder L. The role of LIN28B in tumor progression and metastasis in solid tumor entities. Oncol Res, 2023, 31(2): 101-115. doi: 10.32604/or.2023.028105 pmid: 37304235
[32]	Graf R, Munschauer M, Mastrobuoni G, Mayr F, Heinemann U, Kempa S, Rajewsky N, Landthaler M. Identification of LIN28B-bound mRNAs reveals features of target recognition and regulation. RNA Biol, 2013, 10(7): 1146-1159. doi: 10.4161/rna.25194 pmid: 23770886
[33]	Wilbert ML, Huelga SC, Kapeli K, Stark TJ, Liang TY, Chen SX, Yan BY, Nathanson JL, Hutt KR, Lovci MT, Kazan H, Vu AQ, Massirer KB, Morris Q, Hoon S, Yeo GW. LIN28 binds messenger RNAs at GGAGA motifs and regulates splicing factor abundance. Mol Cell, 2012, 48(2): 195-206. doi: 10.1016/j.molcel.2012.08.004 pmid: 22959275
[34]	Xu TP, Yu T, Xie MY, Fang Y, Xu TT, Pan YT, Ma P, Shu YQ. LOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA. Gastric Cancer, 2022, 26(2): 169-186.
[35]	Polesskaya A, Cuvellier S, Naguibneva I, Duquet A, Moss EG, Harel-Bellan A. Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency. Genes Dev, 2007, 21(9): 1125-1138.
[36]	Missios P, da Rocha EL, Pearson DS, Philipp J, Aleman MM, Pirouz M, Farache D, Franses JW, Kubaczka C, Tsanov KM, Jha DK, Pepe-Mooney B, Powers JT, Gregory RI, Lee AS, Dominguez D, Ting DT, Daley GQ. LIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy. J Clin Invest, 2021, 131(22): e145142.
[37]	Wang YC, Chen YL, Yuan RH, Pan HW, Yang WC, Hsu HC, Jeng YM. Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. Carcinogenesis, 2010, 31(9): 1516-1522.
[38]	Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers, 2021, 7(1): 6. doi: 10.1038/s41572-020-00240-3 pmid: 33479224
[39]	Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ. Cholangiocarcinoma. Nat Rev Dis Primers, 2021, 7(1): 65. doi: 10.1038/s41572-021-00300-2 pmid: 34504109
[40]	Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology, 2013, 145(6): 1215-1229. doi: 10.1053/j.gastro.2013.10.013 pmid: 24140396
[41]	von Schweinitz D. Hepatoblastoma: recent developments in research and treatment. Semin Pediatr Surg, 2012, 21(1): 21-30. doi: 10.1053/j.sempedsurg.2011.10.011 pmid: 22248967
[42]	Tian N, Shangguan WB, Zhou ZL, Yao Y, Fan CL, Cai LJ. Lin28b is involved in curcumin-reversed paclitaxel chemoresistance and associated with poor prognosis in hepatocellular carcinoma. J Cancer, 2019, 10(24): 6074-6087. doi: 10.7150/jca.33421 pmid: 31762817
[43]	Fang T, Lv HW, Wu FQ, Wang CZ, Li T, Lv GS, Tang L, Guo LN, Tang SH, Cao D, Wu MC, Yang W, Wang HY. Musashi 2 contributes to the stemness and chemoresistance of liver cancer stem cells via LIN28A activation. Cancer Lett, 2017, 384: 50-59. doi: S0304-3835(16)30614-0 pmid: 27721018
[44]	Xu WP, Yi M, Li QQ, Zhou WP, Cong WM, Yang Y, Ning BF, Yin C, Huang ZW, Wang J, Qian H, Jiang CF, Chen YX, Xia CY, Wang HY, Zhang X, Xie WF. Perturbation of MicroRNA-370/Lin-28 homolog A/nuclear factor kappa B regulatory circuit contributes to the development of hepatocellular carcinoma. Hepatology, 2013, 58(6): 1977-1991.
[45]	Puthdee N, Khramchantuk S, Nuwongsri P. LIN28B enhanced STAT3 signaling regulates inflammatory response and chemotherapeutic resistance in cholangiocytes. Asian Pac J Cancer Prev, 2021, 22(11): 3671-3678.
[46]	Ding B, Song YH, Liu SL, Peng C, Zhang YJ. Mechanisms underlying the changes in acetaldehyde dehydrogenase 1 in cholangiocarcinoma. J Cancer, 2023, 14(17): 3203-3213. doi: 10.7150/jca.86967 pmid: 37928420
[47]	Sun YS, Zhao Z, Yang ZN, Xu F, Lu HJ, Zhu ZY, Shi W, Jiang JM, Yao PP, Zhu HP. Risk factors and preventions of breast cancer. Int J Biol Sci, 2017, 13(11): 1387-1397.
[48]	Waks AG, Winer EP. Breast cancer treatment. JAMA, 2019, 321(3): 316.
[49]	de Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol, 2010, 137(2): 183-192.
[50]	Borri F, Granaglia A. Pathology of triple negative breast cancer. Semin Cancer Biol, 2021, 72: 136-145. doi: 10.1016/j.semcancer.2020.06.005 pmid: 32544511
[51]	Yin L, Duan JJ, Bian XW, Yu SC. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res, 2020, 22(1): 61. doi: 10.1186/s13058-020-01296-5 pmid: 32517735
[52]	Feng C, Neumeister V, Ma W, Xu J, Lu LG, Bordeaux J, Maihle NJ, Rimm DL, Huang YQ. Lin28 regulates HER2 and promotes malignancy through multiple mechanisms. Cell Cycle, 2012, 11(13): 2486-2494. doi: 10.4161/cc.20893 pmid: 22713243
[53]	Shen HH, Yang Y, Zhao L, Yuan JY, Niu Y. Lin28A and androgen receptor expression in ER-/Her2+ breast cancer. Breast Cancer Res Treat, 2016, 156(1): 135-147.
[54]	Shen HH, Zhao L, Feng XL, Xu C, Li CY, Niu Y. Lin28A activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2+ breast cancer. Oncotarget, 2016, 7(37): 60407-60418. doi: 10.18632/oncotarget.11004 pmid: 27494865
[55]	Xie RL, Wang YR, Nie WW, Huang WS, Song W, Wang ZX, Guan XX. Lin28B expression correlates with aggressive clinicopathological characteristics in breast invasive ductal carcinoma. Cancer Biother Radiopharm, 2014, 29(5): 215-220.
[56]	Ji W, Diao YL, Qiu YR, Ge J, Cao XC, Yu Y. LINC00665 promotes breast cancer progression through regulation of the miR-379-5p/LIN28B axis. Cell Death Dis, 2020, 11(1): 16. doi: 10.1038/s41419-019-2213-x pmid: 31907362
[57]	Tu HC, Schwitalla S, Qian ZR, LaPier GS, Yermalovich A, Ku YC, Chen SC, Viswanathan SR, Zhu H, Nishihara R, Inamura K, Kim SA, Morikawa T, Mima K, Sukawa Y, Yang JH, Meredith G, Fuchs CS, Ogino S, Daley GQ. LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans. Genes Dev, 2015, 29(10): 1074-1086.
[58]	Shu ZQ, Fan MH, Tu B, Tang ZH, Wang HJ, Li HM, Li HC, Yuan M, Bai JR, Huo SH, Wang LN, Zhu WG, Wang W, Liu XY, Shu SK, Zhao Y. The Lin28b/Wnt5a axis drives pancreas cancer through crosstalk between cancer associated fibroblasts and tumor epithelium. Nat Commun, 2023, 14(1): 6885. doi: 10.1038/s41467-023-42508-8 pmid: 37898598
[59]	Qiu JL, Huang PZ, You JH, Zou RH, Wang L, Hong J, Li BK, Zhou K, Yuan YF. LIN28 expression and prognostic value in hepatocellular carcinoma patients who meet the Milan criteria and undergo hepatectomy. Chin J Cancer, 2012, 31(5): 223-232.
[60]	Puthdee N, Sriswasdi S, Pisitkun T, Ratanasirintrawoot S, Israsena N, Tangkijvanich P. The LIN28B/TGF-β/TGFBI feedback loop promotes cell migration and tumour initiation potential in cholangiocarcinoma. Cancer Gene Ther, 2022, 29(5): 445-455.
[61]	Xu CY, Shen JG, Xie SD, Jiang ZN, Huang LM, Wang LB. Positive expression of Lin28 is correlated with poor survival in gastric carcinoma. Med Oncol, 2013, 30(1): 382. doi: 10.1007/s12032-012-0382-x pmid: 23292830
[62]	Hu Q, Peng J, Liu WP, He XL, Cui L, Chen XL, Yang M, Liu HQ, Liu SL, Wang H. Lin28B is a novel prognostic marker in gastric adenocarcinoma. Int J Clin Exp Pathol, 2014, 7(8): 5083-5092.
[63]	Hamano R, Miyata H, Yamasaki M, Sugimura K, Tanaka K, Kurokawa Y, Nakajima K, Takiguchi S, Fujiwara Y, Mori M, Doki Y. High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer. Br J Cancer, 2012, 106(8): 1415-1423.
[64]	Cao DF, Allan RW, Cheng L, Peng Y, Guo CC, Dahiya N, Akhi S, Li JP. RNA-binding protein LIN28 is a marker for testicular germ cell tumors. Hum Pathol, 2011, 42(5): 710-718. doi: 10.1016/j.humpath.2010.09.007 pmid: 21288558
[65]	Xue DB, Peng Y, Wang FH, Allan RW, Cao DF. RNA-binding protein LIN28 is a sensitive marker of ovarian primitive germ cell tumours. Histopathology, 2011, 59(3): 452-459.
[66]	Lu LG, Katsaros D, Shaverdashvili K, Qian BY, Wu YX, de la Longrais IAR, Preti M, Menato G, Yu H. Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. Eur J Cancer, 2009, 45(12): 2212-2218. doi: 10.1016/j.ejca.2009.05.003 pmid: 19477633
[67]	Granados-Romero JJ, Valderrama-Treviño AI, Contreras- Flores EH, Barrera-Mera B, Herrera Enríquez M, Uriarte-Ruíz K, Ceballos-Villalba JC, Estrada-Mata AG, Alvarado Rodríguez C, Arauz-Peña G. Colorectal cancer: a review. Int J Res Med Sci, 2017, 5(11): 4667.
[68]	Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin, 2020, 70(3): 145-164.
[69]	Pang MH, Wu G, Hou XL, Hou NY, Liang LQ, Jia GQ, Shuai P, Luo B, Wang K, Li GX. LIN28B promotes colon cancer migration and recurrence. PLoS One, 2014, 9(10): e109169.
[70]	Suzuki K, Masuike Y, Mizuno R, Sachdeva UM, Chatterji P, Andres SF, Sun WP, Klein-Szanto AJ, Besharati S, Remotti HE, Verzi MP, Rustgi AK. LIN28B induces a differentiation program through CDX2 in colon cancer. JCI Insight, 2021, 6(9): e140382.
[71]	Sugiura K, Masuike Y, Suzuki K, Shin AE, Sakai N, Matsubara H, Otsuka M, Sims PA, Lengner CJ, Rustgi AK. LIN28B promotes cell invasion and colorectal cancer metastasis via CLDN1 and NOTCH3. JCI Insight, 2023, 8(14): e167310.
[72]	Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. Int J Mol Sci, 2017, 18(7): 1338.
[73]	Kugel S, Sebastián C, Fitamant J, Ross KN, Saha SK, Jain E, Gladden A, Arora KS, Kato Y, Rivera MN, Ramaswamy S, Sadreyev RI, Goren A, Deshpande V, Bardeesy N, Mostoslavsky R. SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell, 2016, 165(6): 1401-1415. doi: S0092-8674(16)30476-7 pmid: 27180906
[74]	Pereira BA, Vennin C, Papanicolaou M, Chambers CR, Herrmann D, Morton JP, Cox TR, Timpson P. CAF subpopulations: a new reservoir of stromal targets in pancreatic cancer. Trends Cancer, 2019, 5(11): 724-741. doi: S2405-8033(19)30193-1 pmid: 31735290
[75]	Franses JW, Philipp J, Missios P, Bhan I, Liu A, Yashaswini C, Tai E, Zhu HL, Ligorio M, Nicholson B, Tassoni EM, Desai N, Kulkarni AS, Szabolcs A, Hong TS, Liss AS, Fernandez-del Castillo C, Ryan DP, Maheswaran S, Haber DA, Daley GQ, Ting DT. Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. Nat Commun, 2020, 11(1): 3303. doi: 10.1038/s41467-020-17150-3 pmid: 32620742
[76]	Pan L, Gong ZH, Zhong ZW, Dong Z, Liu Q, Le YP, Guo JM. Lin-28 reactivation is required for let-7 repression and proliferation in human small cell lung cancer cells. Mol Cell Biochem, 2011, 355(1-2): 257-263. doi: 10.1007/s11010-011-0862-x pmid: 21553022
[77]	Yin J, Zhao J, Hu WM, Yang GP, Yu H, Wang RH, Wang LJ, Zhang GQ, Fu WF, Dai L, Li WZ, Liao BY, Zhang SX. Disturbance of the let-7/LIN28 double-negative feedback loop is associated with radio- and chemo-resistance in non-small cell lung cancer. PLoS One, 2017, 12(2): e0172787.
[78]	Zhang YT, Zhao YL, Wu JG, Liangpunsakul S, Niu JQ, Wang L. MicroRNA-26-5p functions as a new inhibitor of hepatoblastoma by repressing lin‐28 homolog B and aurora kinase A expression. Hepatol Commun, 2018, 2(7): 861-871.

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

Progress on the role of LIN28A/B in tumor development and progression

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 78

Related Articles 0

Recommended Articles

Metrics

Comments